Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | Peer Perform | Wolfe Research | |
| 7/1/2024 | $140.00 → $115.00 | Overweight → Neutral | Piper Sandler |
| 5/30/2024 | $129.00 | Neutral | Goldman |
| 5/21/2024 | $150.00 | Hold → Buy | Argus |
| 1/4/2024 | $135.00 → $125.00 | Outperform → In-line | Evercore ISI |
| 10/20/2023 | $120.00 | Neutral | ROTH MKM |
| 8/28/2023 | $139.00 | Neutral → Buy | BTIG Research |
| 5/3/2023 | Underperform → Neutral | BofA Securities |
Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price target from $130 to $117.
Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight and lowers the price target from $130 to $120.
Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $134 to $120.
WARSAW, Ind., Nov. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will participate in the Citi Global Healthcare Conference on December 5, 2024, with a fireside chat at 8:45 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio d
WARSAW, Ind., and ZURICH, Nov. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision Knee System. This addition to the Persona family builds on Zimmer Biomet's commitment to personalized solutions, providing surgeons with advanced tools for revision knee arthroplasty. "After the successful introduction of Persona Revision Knee in the United States and other markets, the CE Mark certification and commercial launch extends its availability significantly so that more surgeons have
Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform
Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously
Goldman initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $129.00
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
CERT - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-A12B - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su
Third quarter net sales of $1.824 billion increased 4.0% and 4.1% on a constant currency1 basisThird quarter diluted earnings per share were $1.23; adjusted1 diluted earnings per share were $1.74Company updates 2024 financial guidance, reducing and narrowing range for full year outlookWARSAW, Ind., Oct. 30, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2024. The Company reported third quarter net sales of $1.824 billion, an increase of 4.0% over the prior year period, and an increase of 4.1% on a constant currency1 basis. Net earnings for the third quarter were $249.1 million, or $353.2 million on
WARSAW, Ind., Oct. 9, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, October 30, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do
WARSAW, Ind., Aug. 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2024. The cash dividend of $0.24 per share is payable on or about October 31, 2024 to stockholders of record as of the close of business on September 30, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.